References
- 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424. DOI: 10.3322/caac.2149210.3322/caac.2149230207593
- 2. Wong MCS, Fung FDH, Leung C, Cheung WWL, Gog-gins WB, Ng CF. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018 18;8(1):1129. DOI: 10.1038/s41598-018-19199-z10.1038/s41598-018-19199-z577368429348548
- 3. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466-465; discussion 475-477. DOI: 10.1016/j.eururo.2005.12.03110.1016/j.eururo.2005.12.03116442208
- 4. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pi-eiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009 Nov;182(5):2195-203. DOI: 10.1016/j. juro.2009.07.016
- 5. Rayn KN, Hale GR, Grave GP-L, Agarwal PK. New therapies in nonmuscle invasive bladder cancer treatment. Indian J Urol. 2018 Mar;34(1):11-9. DOI: 10.4103/iju.IJU_296_1710.4103/iju.IJU_296_17576924329343907
- 6. Isharwal S, Konety B. Non-muscle invasive blad-der cancer risk stratification. Indian J Urol. 2015 Dec;31(4):289-96. DOI: 10.4103/0970-1591.16644510.4103/0970-1591.166445462691226604439
- 7. Veeratterapillay R, Heer R, Johnson MI, Persad R, Bach C. High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage. Curr Urol Rep. 2016 Sep;17(9):68. DOI: 10.1007/s11934-016-0625-z10.1007/s11934-016-0625-z498040527492610
- 8. Konety BR, Williams RD. Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder. BJU Int. 2004 Jul;94(1):18-21. DOI: 10.1111/j.1464-410X.2003.04894.x10.1111/j.1464-410X.2003.04894.x15217424
- 9. Rouprêt M, Seisen T, Compérat E, Larré S, Mazerolles C, Gobet F, et al. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multi-center study with central pathology review. J Urol. 2013 Jun;189(6):2069-76. DOI: 10.1016/j.juro.2012.11.12010.1016/j.juro.2012.11.12023201497
- 10. Baranyi M, Lippai M, Szatmári Z. [Role of the stroma in the initiation and progression of tumors]. Orv Hetil. 2015 Nov 8;156(45):1816-23. DOI: 10.1556/650.2015.3029410.1556/650.2015.3029426522855
- 11. Vartolomei MD, Mathieu R, Margulis V, Karam JA, Rouprêt M, Lucca I, et al. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World J Urol. 2017 Jan;35(1):121-30. DOI: 10.1007/s00345-016-1848-910.1007/s00345-016-1848-9523373027209168
- 12. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013 Jul 23;109(2):416-21. DOI: 10.1038/bjc.2013.33210.1038/bjc.2013.332372139223799847
- 13. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013 Dec;190(6):1999-2004. DOI: 10.1016/j. juro.2013.06.082
- 14. Mbeutcha A, Rouprêt M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol. 2017 Mar;35(3):337-53. DOI: 10.1007/s00345-016-1826-210.1007/s00345-016-1826-227101100
- 15. Mathieu R, Vartolomei MD, Mbeutcha A, Karakiewicz PI, Briganti A, Roupret M, et al. Urothelial cancer of the upper urinary tract: emerging biomarkers and integrative models for risk stratification. Minerva Urol Nefrol. 2016 Aug;68(4):381-95.
- 16. Lucca I, Jichlinski P, Shariat SF, Rouprêt M, Rieken M, Kluth LA, et al. The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. Eur Urol Focus. 2016 Apr;2(1):79-85. DOI: 10.1016/j.euf.2015.03.00110.1016/j.euf.2015.03.00128723455
- 17. Tang X, Du P, Yang Y. The clinical use of neutro-phil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis. Int J Clin Oncol. 2017 Oct;22(5):817-25. DOI: 10.1007/s10147-017-1171-510.1007/s10147-017-1171-528752351
- 18. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol. 2018;73(1):111-22. DOI: 10.1016/j.eururo.2017.07.03610.1016/j.eururo.2017.07.03628867446
- 19. Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B, et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. Urol Oncol. 2018;36(9):389-99. DOI: 10.1016/j.urolonc.2018.05.01410.1016/j.urolonc.2018.05.01429884342
- 20. Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol. 2005 Apr;13(2):143-53. DOI: 10.1177/10668969050130020310.1177/10668969050130020315864376
- 21. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008 Aug;54(2):303-14. DOI: 10.1016/j. eururo.2008.04.051
- 22. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71(3):447-61. DOI: 10.1016/j.eururo.2016.05.04110.1016/j.eururo.2016.05.04127324428
- 23. Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2017;119(3):371-80. DOI: 10.1111/bju.1376010.1111/bju.13760531560228058776
- 24. Newson, R. B. (2010). Comparing the Predictive Powers of Survival Models Using Harrell’s C or Somers’ D. The Stata Journal, 10(3), 339-358. DOI: 10.1177/1536867X100100030310.1177/1536867X1001000303
- 25. Mathieu R, Lucca I, Rouprêt M, Briganti A, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. 2016;13(8):471-9. DOI: 10.1038/nrurol.2016.12610.1038/nrurol.2016.12627431340
- 26. Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, et al. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2018;16(6):445-52. DOI: 10.1016/j.clgc.2018.07.00310.1016/j.clgc.2018.07.00330077463
- 27. Ojerholm E, Smith A, Hwang W-T, Baumann BC, Tucker KN, Lerner SP, et al. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer. 2017 Mar 1;123(5):794-801. DOI: 10.1002/cncr.3042210.1002/cncr.30422531987527787873
- 28. Vollmer RT. A Review of Outcomes for Stage Ta Bladder Tumors. Am J Clin Pathol. 2016 Aug;146(2):215-20. DOI: 10.1093/ajcp/aqw10310.1093/ajcp/aqw10327473739
- 29. Balan D, Martha O, Chibelean CB, Tataru S, Voidezan S, Sin A, et al. Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors. Medicine (Baltimore). 2018 Apr;97(16):e0522. DOI: 10.1097/MD.000000000001052210.1097/MD.0000000000010522591667329668641
- 30. Celik O, Akand M, Keskin MZ, Yoldas M, Ilbey YO. Preoperative neutrophil-to-lymphocyte ratio (NLR) may be predictive of pathologic stage in patients with bladder cancer larger than 3 cm. Eur Rev Med Pharmacol Sci. 2016;20(4):652-6.
- 31. Mano R, Baniel J, Shoshany O, Margel D, Bar-On T, Nativ O, et al. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. Urol Oncol. 2015 Feb;33(2):67.e1-7. DOI: 10.1016/j.urolonc.2014.06.01010.1016/j.urolonc.2014.06.01025060672
- 32. Schulz GB, Grimm T, Buchner A, Jokisch F, Grab-bert M, Schneevoigt B-S, et al. Prognostic Value of the Preoperative Platelet-to-leukocyte Ratio for Onco-logic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer. Clin Genitourin Cancer. 2017;15(6):e915-21. DOI: 10.1016/j.clgc.2017.05.00910.1016/j.clgc.2017.05.00928587816
- 33. Dai J, Tang K, Xiao W, Yu G, Zeng J, Li W, et al. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15(8):3369-75. DOI: 10.7314/APJCP.2014.15.8.336910.7314/APJCP.2014.15.8.336924870724
- 34. Gierth M, Mayr R, Aziz A, Krieger S, Wullich B, Pycha A, et al. Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy. J Cancer Res Clin Oncol. 2015 Oct;141(10):1819-26. DOI: 10.1007/s00432-015-1957-710.1007/s00432-015-1957-725832016
- 35. Martha O, Porav-Hodade D, Bălan D, Tătaru OS, Sin A, Chibelean CB, et al. Easily Available Blood Test Neutrophil-To-Lymphocyte Ratio Predicts Progression in High-Risk Non-Muscle Invasive Bladder Cancer. Rev Romana Med Lab. 2017;25(2):181-9. DOI: 10.1515/rrlm-2017-001610.1515/rrlm-2017-0016